RERasmia Elgohary

Rasmia Elgohary

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rasmia Elgohary has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum S100 calcium-binding protein P in systemic lupus erythematosus patients with lupus nephritis and thrombotic microangiopathy: a 12-month longitudinal biomarker study

    by Rasmia Elgohary, Ahmed Fayed, Mohamed Abdelkader Morad, Karem Mohamed Salem, Gehad Maghraby

    Purpose: Lupus nephritis (LN) complicated by thrombotic microangiopathy (TMA) represents a severe renal phenotype characterized by immune-mediated inflammation and microvascular injury. S100 calcium-binding protein P (S100P) participates in inflammatory and stress-related signaling, providing a biological rationale for evaluating its potential as a circulating biomarker in LN-TMA. Methods: In this single-center longitudinal biomarker study nested within an observational cohort, 100 patients with systemic lupus erythematosus (SLE) and biopsy-confirmed proliferative LN (ISN/RPS class III or IV) with concomitant TMA were evaluated together with 50 age- and sex-matched healthy participants included for baseline biomarker comparison. Serum S100P was measured at baseline and at 6 and 12 months, and longitudinal changes were examined in relation to renal response, conventional laboratory parameters, SLEDAI-2 K, and renal histopathological indices. Results: Baseline serum S100P was markedly higher in patients with LN-TMA than in healthy participants [median 21.3 (IQR 19.1–24.0) versus 0.1 (0.1–1.0) ng/mL; P < 0.001]. Baseline S100P was not significantly associated with SLEDAI-2 K or renal biopsy activity and chronicity indices. At 6 months, partial responders had lower S100P concentrations than nonresponders [8.5 (7.6–9.2) versus 12.4 (8.6–23.2) ng/mL; P = 0.004; AUC = 0.811]. At 12 months, complete responders had substantially lower concentrations than nonresponders [7.5 (6.7–8.4) versus 27.3 (24.3–29.3) ng/mL; P < 0.001; AUC = 0.967]. Longitudinal S100P changes were associated with changes in creatinine, lactate dehydrogenase, C3, and C4. Conclusion: In this single-center LN-TMA cohort, serum S100P was markedly elevated compared with healthy participants and declined substantially among patients achieving renal response. These findings support an association between longitudinal S100P changes and treatment response but do not establish disease specificity or pretreatment predictive value. S100P should therefore be considered a candidate complementary monitoring biomarker requiring validation in larger multicenter cohorts with appropriate disease-control groups.

  • Open Access

    Genetic and epigenetic insights into systemic lupus erythematosus: linking long non-coding RNA growth arrest-specific transcript 5 and interferon signature

    by Gehad Gamal Maghraby, Manal Abdel-Moneim El-Menyawi, Hanan A. Abdel Rehiem, Olfat Gamil Shaker, Mina M. Habib, Rasmia Elgohary

    Gehad Gamal Maghraby, M.D., F.R.C.P., Manal Abdel-Moneim El-Menyawi, M.D., Hanan A. Abdel Rehiem, M.D., Olfat Gamil Shaker, M.D., Mina M. Habib, M.D., Rasmia Elgohary, M.D.. J Rheum Dis -0001;0:. https://doi.org/10.4078/jrd.2025.0074


  • Open Access

    Assessment of validity, reliability, and feasibility of OMERACT ultrasound knee osteoarthritis scores in Egyptian patients with primary knee osteoarthritis

    by Manal Abd El Moniem El Menyawi, Galila Gamal, Hoda Abdelbadie, Rasmia Elgohary

    Background: Ultrasound (US) can evaluate all joint components affected by knee osteoarthritis (KOA); however, standardized scoring of US-detected pathology is needed to improve its diagnostic and monitoring capabilities. Objectives: To examine the validity, reliability, and feasibility of the Outcome Measures in Rheumatology (OMERACT) ultrasound scoring for KOA, comparing with clinical and radiography measures, using predefined cutoff values. Methods: This cross-sectional study included 75 Egyptian patients with primary KOA. All patients had Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, bilateral knee radiography, and ultrasonography. Inter-observer reliability of ultrasound was evaluated in 30 knees by another newly trained operator. Results: Most of the OMERACT-US KOA scores showed significant associations with WOMAC clinical scores, except for femoral cartilage damage and effusion. The synovitis score was significantly associated with WOMAC–pain score (p-value 0.046), while medial meniscus extrusion (MME) and medial osteophytes were significantly associated with WOMAC–stiffness score (p-value 0.009 and 0.023, respectively). MME and synovitis were significantly associated with WOMAC–physical score (p-value 0.035 and 0.020, respectively). The ultrasound scores also showed a strong correlation with radiographic scoring. Inter-observer reliability ranged from moderate to excellent agreement (k = 0.58 to k = 0.83); it was highest for lateral osteophytes (k = 0.83), good agreement for synovitis (k = 0.72), any osteophytes (k = 0.71), damage of femoral cartilage (k = 0.70), and moderate agreement for medial osteophytes (k = 0.58) and MME (k = 0.59). Conclusion: OMERACT-US scoring system for KOA demonstrated validity, reliability, and feasibility for evaluating both structural and inflammatory components. Using cutoff values improved the scoring reliability for osteophytes and MME. Key Points• OMERACT-US scores provide a valid assessment of inflammatory and structural components of knee osteoarthritis.• The following changes may improve the performance of the OMERACT-US scores.a. The binary score for effusion and synovial hypertrophy can be omitted, as they have no added value.b. A semi-quantitative grading for effusion may capture the impact of effusion on clinical outcomes.c. Added cutoff values to score medial meniscal extrusion, osteophytes, and pathological effusion improved the respective scores’ reliability.d. Applying the updated OMERACT definition of synovitis.• OMERACT-US scores are reliable to be used with a newly trained operator, particularly when cutoff values are included, and proper training time is provided.• The OMERACT-US score is feasible to be used in clinical practice, as the time taken to perform was short, even for a newly trained operator.


  • Open Access

    AB0129 EXPLORING LONG NON-CODING RNA GAS5 IN SLE PATIENTS AND ITS RELATION TO INTERFERON SIGNATURE

    by G. Maghraby, M. Elmeniawy, H. Mostafa, O. Shaker, M. Habib, R. Elgohary

    Background Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with diverse pathogenesis. Excessive apoptosis and impaired clearance of apoptotic cells are the primary drivers of Interferon I (IFN) signaling pathways. Upregulation of the long noncoding RNA Growth arrest-specific 5 (GAS5) was found to be associated with apoptosis [1]. Oncological studies discovered that GAS5 is regulated by IFN signaling pathways and acts as a positive feedback loop on IFN response [2,3]. In a mouse model, GAS5 was linked to SLE susceptibility [4]. However, the exact mechanism is still unknown. Furthermore, GAS5 has been proposed to act by interfering with glucocorticoid action, with a key role in regulating glucocorticoid resistance and sensitivity [5]. Objectives To evaluate the expression levels of GAS5 in serum of SLE patients in comparison with healthy controls, assess their relation to SLE Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index (SDI), and explore their association with each of the 3 IFN stimulatory genes (MX1, IFI44L, IFIT1) as well as IFN signature to elucidate how GAS5 shares in the pathogenesis of SLE. Methods 30 adult SLE patients and 20 age and sex-matched healthy controls were enrolled. SLE disease activity and damage were assessed by SLEDAI-2K and SDI respectively. The expression levels of GAS5 as well as 3 IFN stimulatory genes (MX1, IFI44L, IFIT1) were measured by quantitative real-time PCR. IFN signature score was calculated as described in a previous study [6]. Results GAS5 expression levels were insignificantly upregulated in SLE patients compared to control (p-value 0.11). At cut-off value 1.3-fold change, GAS5 could discriminate SLE from control (AUC 0.63) with high specificity 100 % and modest sensitivity 63%. Their expression levels were not associated with SLEDAI-2K or SDI scores. GAS5 levels were positively correlated with the cumulative dose of steroids in the last 6 months. However, it was not statistically significant. GAS5 was significantly correlated with IFIT1 gene expression (p-value Conclusion GAS5 may be considered a diagnostic biomarker for SLE, but it is not a reliable biomarker for disease activity or damage. GAS5 is suggested to be incorporated into the IFN signaling pathway in SLE raising possible contribution in SLE pathogenesis. References [1] Kino et al. Noncoding RNA gas5 is a growth arrest–and starvation-associated repressor of the glucocorticoid receptor. Science signaling. 2010. [2] Huang et al. Long non-coding RNA GAS 5 is induced by interferons and plays an antitumor role in esophageal squamous cell carcinoma. Cancer medicine. 2018. [3] Xu et al. Long noncoding RNA GAS5 inhibits proliferation and metastasis in papillary thyroid carcinoma through the IFN/STAT1 signaling pathway. Pathology-Research and Practice. 2022. [4] Haywood et al. Overlapping BXSB congenic intervals, in combination with microarray gene expression, reveal novel lupus candidate genes. Genes & Immunity. 2006. [5] Lucafo et al. Long noncoding RNA GAS5: a novel marker involved in glucocorticoid response. Current molecular medicine. 2015. [6] Feng et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 2006. Scatterplot shows the relation between gene expression levels with each other and with interferon signature score in cases. Acknowledgements We would want to express our gratitude to everyone who took part in this study, both SLE patients, and healthy control individuals. This study was funded by Cairo University. Disclosure of Interests None Declared.

  • Open Access

    Eccentric Versus Concentric Exercises in Patients With Rheumatoid Arthritis and Rotator Cuff Tendinopathy: A Randomized Comparative Study

    by Mina Magdy Wahba, Mona Selim, Mohammed Moustafa Hegazy, Rasmia Elgohary, Mohammed Shawki Abdelsalam

    Objective To determine the efficacy of concentric vs. eccentric exercise in improving shoulder function, pain, and tendon characteristics for patients with rheumatoid arthritis and rotator cuff tendinopathy.Methods Forty patients with rheumatoid arthritis and rotator cuff tendinopathy were divided into either concentric or eccentric exercise groups, with 20 patients in each group. Patients received 12 sessions at a pace of 3 sessions per week. Shoulder Pain and Disability Index (SPADI), the visual analogue scale (VAS), supraspinatus and subscapularis thickness, echo pixels, and the Disease Activity Score-28-erythrocyte sedimentation rate (DAS-28-ESR) were assessed at baseline and post-treatment.Results There was a significant difference between the concentric and eccentric groups regarding SPADI and VAS scores in favor of the eccentric group. However, there was no significant difference between the two groups regarding tendon thickness, echo pixels, or DAS-28-ESR.Conclusion Eccentric exercises were more effective than concentric exercises in improving shoulder function and pain intensity. However, neither of the two types of exercises was superior in improving tendon characteristics or disease activity.


  • Open Access

    IgG4 related pericardium and lung disease in pediatric patient complicated with fatal massive hemoptysis: a case report and review of literature

    by Moustafa Soliman, Hamdy Ahmed, Rasmia Elgohary, Hala Ibrahem El Gendy

    Background: IgG4-related disease (IgG4-RD) is a progressive and sometimes fatal disease that rarely affects pediatric age group. It may affect the orbits, lacrimal and salivary glands, pancreas, kidneys, peritoneum and other organs. Lung and pleura are not commonly reported in IgG4-RD. We here present a rare case of pediatric IgG4-RD with rare involvement of pericardium, pleura and lungs. Case presentation: A 13-year-old girl presented with intrathoracic IgG4-RD with pleuropericardial involvement. She showed initial improvement on prednisolone. Azathioprine and then mycophenolate failed to control relapses during steroid tapering. Her last relapse was treated by rituximab however, the patient developed acute fatal massive hemoptysis. Conclusions: Pediatric IgG4-RD is a rare entity with pericardio-pulmonary affection as the rare of the rare. Usual treatment of prednisolone and steroid sparing agents should be used, with rituximab used as a rescue therapy, but fatal complications may occur.


  • Using Intra-Articular Allogenic Lyophilized growth factors in Primary Knee Osteoarthritis: A Randomized Pilot Study

    by Rasmia El-Gohary, Amany Diab, Hala El-Gendy, Hossam Fahmy, Kamel Heshmat Gado

    Objective: Investigating the safety in addition to clinical and structural efficacy of allogenic lyophilized growth factors (L-GFs) in patients with symptomatic primary knee osteoarthritis. Design:... Lay abstract Knee osteoarthritis affects many people after middle age. It causes progressive joint damage and may lead to disability. To date, there is no medical treatment that can stop disease pr...


  • Open Access

    Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study

    by A. Fayed, M.M. El Menyawi, M. Ghanema, O. Shaker, R. Elgohary

    Much evidence highlighted the role of interferon alpha (IFN-alpha) in systemic lupus erythematosus (SLE) and suggested its possible role in assessing disease activity. We measured serum IFN-alpha in Egyptian SLE patients in order to determine a cutoff value that can be used to distinguish patients from healthy controls and explored its clinical value in monitoring disease activity and different aspects of the disease, in particular lupus nephritis. This cross-sectional, case-control study was conducted on 59 SLE patients and 30 healthy controls. Serum IFN-alpha was measured in all participants using sensitive enzyme-linked immunosorbent assay (ELISA). SLE patients underwent assessment of disease activity using the SLE disease activity index-2000 (SLEDAI-2K) as well as an evaluation of proteinuria, complement C3 and C4, and serology. Patients with evidence of renal involvement underwent renal biopsy. The median serum IFN-alpha was 81.8 pg/mL (interquartile range [IQR] 63.4:102.4), which was significantly higher than in healthy controls (median 10.3 pg/mL [IQR 7.3:11.6]) (p<0.001). At serum level of 14.7 pg/mL, IFN-alpha has high sensitivity and specificity to discriminate SLE patients from controls, with high positive and negative predictive values. Serum IFN-alpha was not associated with markers of disease activity, clinical features and anti-double stranded DNA. Furthermore, it was not associated with markers of renal activity, including proteinuria, C3 and C4 complement factors and histopathology renal classes. Despite elevated levels of serum IFN-alpha in SLE patients, it is not possible to use it as a biomarker for disease activity.